Product Name: Rasagiline mesylate Synonyms: (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate;CS-289;R-(+)-Rasagiline mesylate;N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate;Rasagiline Mesylate/Tartrate/Base;(1R)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden...
Synonyms: Rasagiline Mesylate,Rasagiline Mesilate CAS: 161735-79-1 EC number: 694-423-3 MF: C13H17NO3S MW: 267.344 SECTION 4: First aid measures Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. ...
There is also a concern regarding the potential for formation of alkyl mesylates during the treatment of the free base of a drug substance with MSA if any residues of short-chain alcohols are present. (Snodin D., “Residues of genotoxic alkyl mesylates in mesylate salt drug substances: Real...
Crystalline rasagiline base has lower water solubility than many rasagiline salts, especially the mesylate salt, which is water soluble. The solubility of rasagiline mesylate in water is 92 mg/ml at a pH of 6.7 and 570 mg/ml at a pH of 3.3, both measured at 25° C. At the same tempera...
Available as rasagiline mesylate; dosage expressed in terms of rasagiline.AdultsParkinsonian SyndromeMonotherapy or Adjunctive Therapy with Other Antiparkinsonian Agents (Other than Levodopa) Oral 1 mg once daily.Adjunctive Therapy with Levodopa Oral Initially, 0.5 mg once daily....
Rasagiline mesylate (RM) is a monoamine oxidase inhibitor that is commonly used to alleviate the symptoms of Parkinson’s disease. However, it suffers from low oral bioavailability due to its extensive hepatic metabolism in addition to its hydrophilic nature which limits its ability to pass through...
Crystalline rasagiline base may be used as a synthetic intermediate to be used to attain a rasagiline salt, such as rasagiline mesylate or rasagiline tartrate. The crystalline rasagiline base may be dissolved in a solvent and reacted with an acid to form a pharmaceutically acceptable acid addition...
The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less
Pat. No. 6,630,514, more preferably, rasagiline mesylate.In a further particular embodiment, the active agent is the rasagiline metabolite 1-aminoindan, or a pharmaceutically acceptable salt thereof.In still other particular embodiments, the active agent is an analog of N-propargyl-1-aminoindan,...